Comments
Drug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.
Lupin Pharmaceuticals launched GAVIS Pharmaceuticals’ Zolpidem Sublingual tablets after having received final approval from the US Food and Drug Administration (FDA) as well as from the FTC with 180 days of exclusivity.
Reacting to the news, the Lupin stock was trading at Rs 1,465.30 on the BSE, up 0.27 per cent from the previous close.
Lupin had completed the acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS) in a $880-million deal earlier this month.
It had announced the acquisition on July 23, 2015.
GAVIS’s product is the generic equivalent of Purdue Pharma LP’s Intermezzo Sublingual tablets and is indicated for the treatment of insomnia.
According to the IMS sales data, Intermezzo had sales of $9.46 million in the US market.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.